Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.
Oct 1, 2015
Sep 25, 2015
Celgene's VIDAZA® (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Nov 5, 2015 at 9:00 AM ET